Wednesday, July 8, 2026

Patent intelligence · US

US 10258576

Particulate comprising a calcium-containing compound and a sugar alcohol

granted A61KA61K9/0056A61K9/1623A61K9/2004
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 13
Applicant portfolio 1,436
Related coverage 1
Patent details — US 10258576

Quick answer

US 10258576 (Particulate comprising a calcium-containing compound and a sugar alcohol) is held by TAKEDA AS. Status: granted. Granted Apr 16, 2019. Expires Apr 11, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
TAKEDA AS
Grant date
Expiration
Claims
25
CPC classes
A61K, A61K9/0056, A61K9/1623, A61K9/2004, A61K9/2018, A61K9/2077

More from TAKEDA AS

Related pharmaceutical patents in our USPTO index.

  1. US 12428403

    N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists

    Takeda Pharmaceutical Company Limited · Expires Sep 25, 2045

    granted
  2. US 12421188

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  3. US 12419890

    Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  4. US 12415866

    Monoclonal antibody inhibitor of Factor XIIa

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  5. US 12415782

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  6. US 12409210

    CNS delivery of therapeutic agents

    Takeda Pharmaceutical Company Limited · Expires Sep 4, 2045

    granted
  7. US 12404237

    Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted
  8. US 12403154

    Administration of sting agonist and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted

Related coverage

Frequently asked questions

What is US patent 10258576?

US 10258576 (Particulate comprising a calcium-containing compound and a sugar alcohol) is held by TAKEDA AS. Status: granted. Granted Apr 16, 2019. Expires Apr 11, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10258576?

TAKEDA AS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.

When does US 10258576 expire?

Our index shows an expiration date of Apr 11, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.